Search
Larotrectinib shows promise in paediatric patients with TRK gene mutations
- OPACC
- Apr 9, 2018
- 1 min read
A new cancer drug has proven safe and effective for pediatric patients with a rare tumour gene mutation. The study tested the safety and dose of larotrectinib (LOXO-195) in paediatric patients with a mutation known as tropomyosin receptor kinases (TRK) that can occur in a variety of tumour types.
Recent Posts
See AllA team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...